

Acute Lymphoblastic Lymphoma




Relapsed or Refractory




CCT5029
[Phase I/Ib Autologous CD22 Chimeric Antigen Receptor \(CAR\) T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies](#)
 PI: Frank
 Sponsor: Stanford University



CCT5079
[Phase Ib Study of Brexucabtagene AutoleuCEL plus Dasatinib in Adults with Acute Lymphoblastic Leukemia](#)
 PI: Muffy
 Sponsor: Stanford University

CCT5084
 Phase I/II Dose-Exploration & Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed / Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
 PI: Weng
 Sponsor: Beam Therapeutics Inc.

KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
-  [Link](#) Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy